Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(0.19)
# 4,589
Out of 4,993 analysts
231
Total ratings
38.4%
Success rate
-7.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABEO Abeona Therapeutics | Initiated Coverage: Buy | $17 | $5.67 | +199.82% | 1 | Sep 19, 2026 | |
| MNOV MediciNova | Initiated Coverage: Buy | $6 | $3.30 | +81.82% | 1 | Sep 19, 2026 | |
| ANVS Annovis Bio | Reiterated: Buy | $7 | $1.19 | +488.24% | 3 | Sep 4, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $7 → $8 | $2.71 | +195.20% | 5 | Sep 3, 2026 | |
| IMUX Immunic | Reiterated: Buy | $19 → $29 | $10.83 | +167.77% | 6 | Sep 1, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Hold | $7 | $8.90 | -21.35% | 18 | Aug 25, 2026 | |
| CING Cingulate | Rated: Buy | $10 → $9 | $5.23 | +72.08% | 26 | Aug 24, 2026 | |
| COYA Coya Therapeutics | Reiterated: Buy | $12 | $4.95 | +142.42% | 3 | Aug 23, 2026 | |
| PMN ProMIS Neurosciences | Rated: Buy | $30 → $29 | $13.63 | +112.77% | 3 | Aug 21, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $9 → $7 | $2.41 | +190.46% | 21 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $2.45 | +22.45% | 17 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.84 | +334.78% | 29 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 → $8 | $5.17 | +54.74% | 21 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $11 | $6.64 | +65.66% | 22 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $6.62 | -54.68% | 6 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $31 → $37 | $42.99 | -13.93% | 5 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.50 | +100.00% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.57 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.4211 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.7487 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $53.70 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $22.85 | n/a | 6 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.3 | $17.33 | n/a | 5 | Sep 19, 2023 |
Abeona Therapeutics
Sep 19, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $5.67
Upside: +199.82%
MediciNova
Sep 19, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $3.30
Upside: +81.82%
Annovis Bio
Sep 4, 2026
Reiterated: Buy
Price Target: $7
Current: $1.19
Upside: +488.24%
Ovid Therapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $7 → $8
Current: $2.71
Upside: +195.20%
Immunic
Sep 1, 2026
Reiterated: Buy
Price Target: $19 → $29
Current: $10.83
Upside: +167.77%
Capricor Therapeutics
Aug 25, 2026
Reiterated: Hold
Price Target: $7
Current: $8.90
Upside: -21.35%
Cingulate
Aug 24, 2026
Rated: Buy
Price Target: $10 → $9
Current: $5.23
Upside: +72.08%
Coya Therapeutics
Aug 23, 2026
Reiterated: Buy
Price Target: $12
Current: $4.95
Upside: +142.42%
ProMIS Neurosciences
Aug 21, 2026
Rated: Buy
Price Target: $30 → $29
Current: $13.63
Upside: +112.77%
CervoMed
Aug 20, 2026
Reiterated: Buy
Price Target: $9 → $7
Current: $2.41
Upside: +190.46%
Aug 19, 2026
Reiterated: Buy
Price Target: $3
Current: $2.45
Upside: +22.45%
Aug 18, 2026
Reiterated: Buy
Price Target: $8
Current: $1.84
Upside: +334.78%
Aug 14, 2026
Rated: Buy
Price Target: $9 → $8
Current: $5.17
Upside: +54.74%
Aug 12, 2026
Reiterated: Buy
Price Target: $10 → $11
Current: $6.64
Upside: +65.66%
Jun 10, 2026
Reiterated: Buy
Price Target: $3
Current: $6.62
Upside: -54.68%
May 18, 2026
Rated: Buy
Price Target: $31 → $37
Current: $42.99
Upside: -13.93%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.50
Upside: +100.00%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $13.57
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.4211
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.7487
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $53.70
Upside: n/a
Oct 24, 2023
Reiterated: Hold
Price Target: n/a
Current: $22.85
Upside: n/a
Sep 19, 2023
Reiterated: Hold
Price Target: $0.3
Current: $17.33
Upside: n/a